Category: Research and Development

Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Press Release Jul 11, 2023
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge

The Parkinson's disease market is expected to grow to $12.8 billion by 2028.
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
Press Release Mar 20, 2023
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.